generics
High Court rules against Pfizer in Lyrica patent case
September 10, 2015Medical Communications, Sales and Marketing Actavis, Lyrica, Pfizer, anxiety, epilepsy, generics, neuropathic pain, pregabalin
The High Court of England and Wales today ruled against Pfizer in the patent battle with Actavis on Pfizer’s blockbuster …
Lundbeck sheds 1,000 jobs in £284 million restructure
August 20, 2015Manufacturing and Production, Sales and Marketing Lundbeck, generics, job losses, patents, redundancies, restructure, restructuring
Lundbeck is cutting a thousand jobs globally as part of a restructuring programme to significantly lower its cost and focus …
Pfizer offers to pay for UK Lyrica switches
August 13, 2015Lyrica, NHS England, Pfizer, generics, neuropathic pain, patents, pregabalin
Pfizer is to pay the administrative costs of GPs to switch patients to Lyrica from generic versions of pregabalin, as …
Pfizer and Flynn rapped for overcharging on anti-epilepsy drug
August 6, 2015Manufacturing and Production, Sales and Marketing CMA, Drug pricing, Flynn Pharma, Pfizer, competitions markets authority, epilepsy, generics, phenytoin, pricing
Pharma firms Pfizer and Flynn Pharma have been accused by the UK’s competition watchdog of charging ‘excessive and unfair’ prices …
Teva to switch generics focus to Allergan
July 27, 2015Sales and Marketing Allergan, Teva, generics, mergers and acquisitions, pharma mergers and acquisitions
Teva is in negotiations to buy Allergan’s generics division for upwards of $40 billion, according to reports. The generics firm …
Teva ‘to increase Mylan bid to $43bn’
July 7, 2015Sales and Marketing M&A, MA, Mylan, Teva, generics
Israeli drugmaker Teva is considering whether to up its bid for US rival firm Mylan, with reports that it could …
Mylan tells Teva to ‘stop playing games’ and make firm bid
June 2, 2015Manufacturing and Production, Sales and Marketing M&A, MA, Mylan, Teva, generics
Mylan has written another strongly-worded letter to Teva, this time accusing the Israeli firm of ‘playing games’ and violating US …
Teva forges ahead with Mylan pursuit
May 6, 2015Sales and Marketing Mylan, Perrigo, Teva, generics
Teva has reinforced its commitment to buy Mylan despite previous rejection and only days after Mylan upped its own bid …
M&A drama continues as Mylan rejects Teva
April 28, 2015Sales and Marketing M&A, MA, Mylan, Perrigo, Teva, bids, generics, takeovers
Mylan has firmly rejected Teva’s acquisition bid, even though its own bid for Irish firm Perrigo has also been turned …
Teva moves to buy Mylan
April 21, 2015Research and Development, Sales and Marketing India, Mylan, Perrigo, Teva, US, Vigodman, generics, israel, merger
Israeli generics drug giant Teva has made an offer to buy its US rival Mylan for around $40.1 billion. The …
Daiichi Sankyo to sell Sun Pharma stake
April 21, 2015Manufacturing and Production, Sales and Marketing Daiichi Sankyo, FDA, India, Ranbaxy, Sun Pharma, generics
Daiichi Sankyo is to sell off all or part of its stake in Sun Pharma and back away from the …
Sun Pharma and Ranbaxy merger gets US nod
February 2, 2015Manufacturing and Production, Sales and Marketing India, Ranbaxy, Sun Pharma, US, generics, merger, recall, torrent
The US Federal Trade Commission has given its approval for Sun Pharma’s $4 billion acquisition of troubled Indian firm Ranbaxy …
Actavis buys generics firm for £306 million
January 26, 2015Manufacturing and Production, Sales and Marketing Actavis, Allergan, Auden McKenzie, generics
Actavis is buying UK-based development and marketing firm Auden McKenzie in a deal worth up to £306 million. The move …
New Teva chairman announced
November 28, 2014Manufacturing and Production, Sales and Marketing Phillip Frost, Teva, Yitzhak Peterburg, barer, generics, israel
Teva Pharmaceutical Industries has confirmed that Professor Yitzhak Peterburg is to serve as its new chairman from January. Peterburg who …
UCB sells generics business
November 10, 2014Manufacturing and Production, Sales and Marketing Belgium, UCB, generics, kremers urban, us conern
UCB is to sell its US generics business Kremers Urban to two private equity firms in a $1.5 billion deal. …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
